Mike Gravel, retired, served as a U.S. Senator from Alaska from 1969 to 1981. Senator Gravel sat on the Finance, Interior, Environmental and Public Works committees, and chaired the Energy, Water Resources, Buildings and Grounds and Environmental Pollution subcommittees. Senator Gravel is best known for his work on the Vietnam War. He filibustered for five months which contributed to the end of the military draft. He challenged the U.S. Government by releasing the Pentagon Papers. When the Nixon administration refused to allow the New York Times to publish information on the Pentagon Papers, Senator Gravel attempted to read the entire 7,000 pages of the document into the Senate record. The Supreme Court blocked his attempt. Senator Gravel then wrote The Senator Gravel Edition, The Pentagon Papers in 1971. He again had to go before the Supreme Court and received a ruling that affected the Speech and Debate Clause of the Constitution. In retirement, Gravel has written two books, Jobs and More Jobs, and Citizen Power. Senator Gravel served as a director of Kush, Inc. (“Kush”) from March 2013 to July 2014, prior to its acquisition by the Registrant.

Mr. Henrie began his career with the law firm of Suitter Axland Armstrong and Hanson in Salt Lake City, Utah. Mr. Henrie worked in the banking industry for seven years. At the time, he left banking to enter law school he was a Second Vice President with a subsidiary of Chase Manhattan Corporation. He later joined Fabian & Clendenin in Salt Lake City as a Partner before moving his practice to Las Vegas, Nevada. He was a Founding Member of Eddington Henrie and McArthur. He was the President of the Business Law Section of the Utah State Bar and also of the Estate Planning Section of the Utah State Bar. His various memberships include Attorney and Counsellor of the Supreme Court of the United States, U.S. District Court, District of Utah, Supreme Court of Utah, Nevada State Court System, Utah State Bar, State Bar of Nevada and the Department of Veterans Affairs Accredited. He was an Adjunct Professor of Law in the Masters of Taxation program for the Washington School of Law in Salt Lake City, Utah. Mr. Henrie has written various manuals published by the National Business Institute (“NBI”) on topics including Estate Planning, Corporate Law and Taxation and has lectured widely on those topics for it. He has been a Sole Practitioner since 2003 and maintains law practices in both the State of Utah and the State of Nevada. His practice focus is in the areas of estate planning,securities, corporate structuring, taxation, mergers and acquisitions and business litigation. Mr. Henrie is licensed to practice law in the states of Nevada and Utah and maintains an active practice before the Securities and Exchange Commission.

Bringing over a decade of research experience, Dr. Despanie completed his Pharmaceutical Sciences PhD at the University of Southern California following a BS in Biology from Louisiana State University.

Dr. Despanie began his biomedical career at LSU investigating molecular therapies such as oncolytic virotherapy and antiviral gene silencing before joining Johns Hopkins Hospital to probe how defective protein trafficking contributes to cystic fibrosis.

His dissertation, “Tubulin-based fusion proteins as multifunctional tools”, detailing a novel class of chemotherapy nanomedicines to combat triple-negative breast cancers (an aggressive disease subtype for which there are currently no targeted treatments) received over $178,000 in NIH grant funding.

In 2014, Dr. Despanie also founded S-aima Biopharmaceutics LLC, a biotech startup which sought to develop an artificial blood nanomedicine for temporary blood replacement on the battlefield and during civilian emergencies. An enthusiastic Dr. Despanie affirms, “This is a unique opportunity to leverage my passion for nanomedicine towards designing CBD formulations that will undoubtedly grant us a competitive edge in the marketplace.”

“We are thrilled and honored to have Dr. Jordan Despanie join CBDG. We look forward to working with him as we take CBDGs science to the next level, says Mike Gravel, Chairman and CEO of THC Farmaceuticals, Inc.